文献速递白血病

慢性髓性白血病未达治疗里程碑后的生存分析

Survival with chronic myeloid leukaemia after failing milestones.
PubMed 文献 · Leukemia · 2023-09-19

该研究基于CML-study IV中1342例新诊断慢性期慢性髓性白血病患者,按3、6、12、24个月时BCR::ABL1IS水平分层进行里程碑生存分析,随访至14年。结果显示未达失败里程碑(6个月BCR::ABL1IS>10%、12个月>1%)的患者10至12年生存率约80%,仅比应答患者低10%,提示TKI治疗未达失败里程碑者继续TKI治疗仍可能获益。

要点

  • 未达失败里程碑(6个月BCR::ABL1IS>10%、12个月>1%)患者10至12年生存率约80%,比应答患者低约10%。
  • 年龄(>60岁或≤60岁)对生存差异无重大影响,但对风险比和CML特异性生存有影响。
  • 26.9%的患者换用替代治疗,未改变主要结果。

核心结论

  • TKI治疗未达失败里程碑的患者继续TKI治疗仍可能获益,为面临替代治疗风险的失败患者提供个体化决策依据。

研究设计与样本

  • 来自CML-study IV的1342例新诊断慢性期CML患者,均接受规律分子学检测,按3、6、12、24个月时BCR::ABL1IS水平(<0.1%、0.1-1%、>1-10%、>10%)进行里程碑生存分析,随访至14年。

主要发现

  • 未达失败里程碑(6个月BCR::ABL1IS>10%、12个月BCR::ABL1IS>1%)的患者10至12年生存率约80%,比应答患者低约10%。
  • 年龄(>60岁或≤60岁)对生存差异无重大影响,但对风险比和CML特异性生存有影响。
  • 26.9%的患者换用替代治疗,未改变主要结果。

临床怎么用

  • 作者认为,TKI治疗未达失败里程碑的患者继续TKI治疗仍可能获益,该数据为面临替代治疗风险的失败患者提供个体化决策依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To systematically analyse survival after reaching, or not reaching, response milestones, 1342 patients from CML-study IV with newly diagnosed CML in chronic phase and regular molecular tests were studied. Landmark survival analyses were done by <0.1%, 0.1-1%, >1-10% and >10% BCR::ABL1IS at 3, 6, 12 and 24 months up to 14 years. 10- to 12-year survival of patients who failed the failure milestones (>10% BCR::ABL1IS at 6 months, >1% BCR::ABL1IS at 12 months) ranged around 80%, 10% less than in responding patients. These results suggest revision of milestones. Age (more or less than 60 years) had no major impact on survival differences, but on hazard ratios and CML-specific survival. Switching to alternative therapies, which was observed in 26.9% of the patients, did not change the main results. The data show that TKI-treated patients not reaching failure milestones still may derive benefit from continuing TKI-treatment and provide a basis for individualised decisions, if failing patients are confronted with risks of alternative treatments.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lauseker M, Hehlmann R, Hochhaus A, et al. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023. PMID: 37726340. doi:10.1038/s41375-023-02028-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。